Adaptive Alzheimer’s Drug-Testing Platforms Aim to Speed Trial Decisions

An ARPA-H-backed, four-year initiative involving UC San Diego aims to test five to ten treatment regimens through a reusable platform, with blood biomarkers including p-tau217 used to track early changes. The UK Ad-SMART adaptive trial is testing repurposed drugs such as atomoxetine and metformin, with initial conclusions expected by 2030. These are trial-design developments, not evidence that the treatments work or prevent dementia.